New cancer drug combo tested in tiny trial – but halted early

NCT ID NCT06274437

Terminated Disease control Sponsor: Biond Biologics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested an experimental drug called BND-35, alone or combined with nivolumab or cetuximab, in 12 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study was terminated early, so we have limited information on how well it worked.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BND-35 (an experimental antibody), nivolumab (Opdivo), and cetuximab (Erbitux)
What this could lead to: If successful, this could point toward a new treatment option for advanced cancers that have not responded to standard therapies.
What could go wrong: This was a very early phase 1 trial with only 12 participants and has been terminated, so results are limited. The drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER

Contacts and locations

Locations

Hadassah University Medical Center

Jerusalem, 91120, Israel
Rabin Medical Center

Petah Tikva, 49100, Israel
Rambam Health Care Campus

Haifa, 3109601, Israel
Sheba Medical Center

Ramat Gan, 52621, Israel
Tel Aviv Sourasky Medical Center

Tel Aviv, 6423906, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.